ViroGates published a press release yesterday announcing that the Committee for Medicinal Products for Human Use (CHMP), advisory board to the European Medicines Agency (EMA), has adopted a positive opinion of Kineret (anakinra) for suPAR-guided treatment of adult patients with COVID-19 pneumonia.
The full press release can be found here. CEO Jakob Knudsen was interviewed today by Alf Riple, Chief Analyst at Västra Hamnen Corporate Finance, about the significance of this announcement and its impact on ViroGates going forward.
The video clip is available here.
This video was created as a part of Market Focus, Västra Hamnen Corporate Finance’ commissioned research offering.
© Modular Finance, source Nordic Press Releases